Non-Melanoma Skin Cancers Coverage from Every Angle
Advertisement
Advertisement

Nikolaos Andreatos, MD, on Adverse Events Following Radiotherapy and Immunotherapy in Patients With Melanoma and Merkel Cell Carcinoma

Posted: Tuesday, June 30, 2020

Nikolaos Andreatos, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses data from a preliminary report of an evolving retrospective registry, which showed that almost half of patients with melanoma and Merkel cell carcinoma developed new immune-related adverse events following radiotherapy, a quarter of whom require hospitalization. These rates raise concern about the additive toxicity of immune checkpoint inhibitors plus radiotherapy.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.